Patient characteristics
| Patient no. . | Age at first CLL treatment, y . | Definition of high risk . | Anti-CD20 Ab . | Previous CLL therapy . |
|---|---|---|---|---|
| 1 | 61 | hCKT∗ | G, R | FCR |
| 2 | 66 | POD <1 year | R | FCR |
| 3 | 52 | del17p, TP53mut | G | GIVe |
| 4 | 61 | del17p, TP53mut | G | GIVe |
| 5 | 74 | del17p, TP53mut, CKT | G | BIG |
| 6 | 92 | del17p | G | BIO |
| 7 | 70 | del17p∗ | G | MCP |
| 8 | 80 | TP53mut, CKT∗ | G, R | BR |
| 9 | 86 | hCKT∗ | G, R | BR |
| 10 | 74 | CKT∗ | G, R | FCR |
| 11 | 74 | del17p | R | BIO |
| 12 | 63 | POD <1 year | R | FCR |
| Patient no. . | Age at first CLL treatment, y . | Definition of high risk . | Anti-CD20 Ab . | Previous CLL therapy . |
|---|---|---|---|---|
| 1 | 61 | hCKT∗ | G, R | FCR |
| 2 | 66 | POD <1 year | R | FCR |
| 3 | 52 | del17p, TP53mut | G | GIVe |
| 4 | 61 | del17p, TP53mut | G | GIVe |
| 5 | 74 | del17p, TP53mut, CKT | G | BIG |
| 6 | 92 | del17p | G | BIO |
| 7 | 70 | del17p∗ | G | MCP |
| 8 | 80 | TP53mut, CKT∗ | G, R | BR |
| 9 | 86 | hCKT∗ | G, R | BR |
| 10 | 74 | CKT∗ | G, R | FCR |
| 11 | 74 | del17p | R | BIO |
| 12 | 63 | POD <1 year | R | FCR |
hCKT included ≥5 cytogenetic aberrations, and CKT included ≥3 and <5 cytogenetic aberrations.
Ab, antibody; B, bendamustine; C, cyclophosphamide; CKT, complex karyotype; F, fludarabine; G, obinutuzumab; hCKT, high complex karyotype; I, ibrutinib; MCP, mitoxantrone, chlorambucil, and prednisolone; mut, mutated; O, ofatumumab; POD, progression of disease after end of therapy; R, rituximab; Ve, venetoclax.
High-risk features were assessed at clinical progression after induction treatment.